Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 May;115(2S):S46-S53.
doi: 10.1016/j.jnma.2023.02.004.

Disparities in lung cancer

Affiliations

Disparities in lung cancer

Narjust Duma et al. J Natl Med Assoc. 2023 May.

Abstract

Lung cancer is the second most common cancer and the leading cause of cancer death among men and women in the United States. Despite a substantial decline in lung cancer incidence and mortality across all races in the last few decades, medically underserved racial and ethnic minority populations continue to carry the greatest burden of disease throughout the lung cancer continuum. Black individuals experience a higher incidence of lung cancer due to lower rates of low-dose computed tomography screening, which translate into advanced disease stage at diagnosis and poorer survival outcomes compared with White individuals. With respect to treatment, Black patients are less likely to receive gold standard surgery, have access to biomarker testing or high-quality treatment compared with White patients. The reasons for those disparities are multifactorial and include socioeconomic (eg, poverty, lack of health insurance, and inadequate education), and geographic inequalities. The objective of this article is to review the sources of racial and ethnic disparities in lung cancer, and to propose recommendations to help address them.

Keywords: Lung cancer; Racial and ethnic disparities; Screening.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest Narjust Duma, MD, Advisory Board: AstraZeneca, Janssen, Pfizer Inc; Nathaniel Evans III, MD, Consultant: Intuitive Surgical (Proctor); Edith Mitchell, MD, MACP, FCPP, FRCP, Consultant: AstraZeneca, Bristol Myers Squibb, Genentech, Merck & Co., Inc., Pfizer Inc., Taiho Oncology, Inc.; Clinical Research: Amgen, Genentech

LinkOut - more resources